Related Experiment Video

Updated: Jun 20, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.1K

Effects of protein restriction on insulin-like growth factor (IGF)-1 in men with prostate cancer: results from a

Maria L Cagigas1, Giovanni Fiorito2,3, Beatrice Bertozzi4

  • 1Faculty of Medicine and Health, Charles Perkins Center, University of Sydney, Camperdown, Australia.

Biomarker Research
|July 22, 2024
PubMed
Abstract

Insights

An isocaloric protein-restricted diet did not lower insulin-like growth factor-1 (IGF-1) or increase IGF binding proteins in men with prostate cancer. Further research is needed for effective dietary interventions.

Area of Science:

  • Oncology
  • Endocrinology
  • Nutritional Science

Background:

  • Insulin-like growth factor-1 (IGF-1) and its binding proteins are implicated in prostate cancer progression.
  • Observational studies suggest protein restriction may lower IGF-1 levels.
  • The effect of isocaloric protein restriction on IGF-1 and IGFBPs in prostate cancer patients remains unclear.

Discussion:

  • This randomized trial investigated the impact of a 4-6 week isocaloric protein-restricted diet on serum IGF-1 and IGF binding proteins (IGFBP-1, IGFBP-3) in men with localized prostate cancer.
  • The study randomized 38 overweight men to either a protein-restricted diet or their usual diet, measuring biomarkers longitudinally.
  • Contrary to the hypothesis, the protein-restricted diet did not significantly reduce IGF-1 or increase IGFBP-1/IGFBP-3.

Key Insights:

  • Isocaloric protein restriction, without calorie restriction, does not significantly alter serum IGF-1 levels in men with localized prostate cancer.
  • The intervention did not lead to an increase in serum IGFBP-1 or IGFBP-3 concentrations.
  • These findings challenge the direct efficacy of this specific dietary approach for modulating IGF-1 in this patient population.

Outlook:

  • Further research is necessary to explore alternative dietary strategies for reducing IGF-1 in prostate cancer patients.
  • Investigating the role of calorie restriction in conjunction with protein restriction may yield different results.
  • Identifying safe and effective dietary interventions remains a critical goal for managing prostate cancer biology.

More Related Videos

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.1K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
163
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
932
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K